• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

    2/12/24 5:11:14 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RVMD alert in real time by email
    SC 13G/A 1 rvmd_13ga.htm
       
       
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC  20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)   *


    Revolution Medicines, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)
     
    76155X100
    (Cusip Number)
     
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     
    ☐
    Rule 13d-1(b)
     
    ☒
    Rule 13d-1(c)
     
    ☐
    Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).







    (Continued on following pages)
    Page 1 of 34 Pages
    Exhibit Index Found on Page 34


    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital Partners, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    California
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    329,602 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    329,602 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    329,602 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.2% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    1 Includes 1,214 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 2 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital Institutional Partners, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    California
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    740,785 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    740,785 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    740,785 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.5% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    1 Includes 3,485 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 3 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital Institutional Partners II, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    California
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    208,623 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    208,623 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    208,623 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.2% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    1 Includes 696 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 4 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital Institutional Partners III, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    88,794 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    88,794 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    88,794 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.1% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    1 Includes 444 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 5 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Four Crossings Institutional Partners V, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    123,849 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    123,849 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    123,849 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.1% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    1 Includes 480 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 6 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital Offshore Investors II, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    1,225,295 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    1,225,295 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    1,225,295 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.7% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    1 Includes 5,809 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 7 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital (AM) Investors, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    71,308 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    71,308 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    71,308 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.0% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    1 Includes 193 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 8 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital F5 Master I, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    275,598 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    275,598 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    275,598 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.2% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    1 Includes 1,029 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 9 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Healthcare Partners Master, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    3,686,350
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    3,686,350
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    3,686,350
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    2.3% 1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    1 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 10 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Partners, L.L.C.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    6,474,606 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    6,474,606 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,474,606 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.0% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    OO

    1 Includes 12,321 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 11 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Institutional (GP) V, L.L.C.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    123,849 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    123,849 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    123,849 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.1% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    OO

    1 Includes 480 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 12 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon F5 (GP), L.L.C.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    275,598 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    275,598 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    275,598 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.2% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    OO

    1 Includes 1,029 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 13 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Healthcare Partners (GP), L.L.C.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    3,686,350
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    3,686,350
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    3,686,350
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    2.3% 1
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    OO

    1 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 14 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Joshua J. Dapice
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    6,750,204 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    6,750,204 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,750,204 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.1% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    1 Includes 13,350 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 15 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Philip D. Dreyfuss
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    6,750,204 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    6,750,204 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,750,204 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.1% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    1 Includes 13,350 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 16 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Hannah E. Dunn
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    6,750,204 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    6,750,204 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,750,204 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.1% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    1 Includes 13,350 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 17 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Richard B. Fried
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    6,750,204 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    6,750,204 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,750,204 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.1% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    1 Includes 13,350 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 18 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Varun N. Gehani
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    6,750,204 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    6,750,204 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,750,204 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.1% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    1 Includes 13,350 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 19 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Nicolas Giauque
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    France
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    6,750,204 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    6,750,204 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,750,204 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.1% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    1 Includes 13,350 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 20 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    David T. Kim
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    6,750,204 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    6,750,204 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,750,204 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.1% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    1 Includes 13,350 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 21 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Michael G. Linn
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    6,750,204 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    6,750,204 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,750,204 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.1% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    1 Includes 13,350 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 22 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Rajiv A. Patel
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    6,750,204 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    6,750,204 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,750,204 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.1% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    1 Includes 13,350 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 23 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Thomas G. Roberts, Jr.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    6,750,204 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    6,750,204 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,750,204 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.1% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    1 Includes 13,350 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 24 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Edric C. Saito
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    6,750,204 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    6,750,204 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,750,204 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.1% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    1 Includes 13,350 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 25 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    William Seybold
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    6,750,204 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    6,750,204 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,750,204 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.1% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    1 Includes 13,350 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 26 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Daniel S. Short
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    6,750,204 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    6,750,204 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,750,204 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.1% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    1 Includes 13,350 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 27 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Andrew J. M. Spokes
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United Kingdom
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    6,750,204 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    6,750,204 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,750,204 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.1% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    1 Includes 13,350 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 28 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    John R. Warren
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    6,750,204 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    6,750,204 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,750,204 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.1% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    1 Includes 13,350 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 29 of 34 Pages

    13G
    CUSIP No. 76155X100
     

    1
    NAMES OF REPORTING PERSONS
     
    Mark C. Wehrly
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                          (a) [     ]
                                                                                                                                                          (b) [ X ]**
    ** The reporting persons making this filing hold an aggregate of 6,736,854 Shares (as defined in Item 2) and hold Warrants (as defined in the Preliminary Note) exercisable for an aggregate of  13,350 Shares.  Accordingly, as of the date of this filing the aggregate Shares and Warrants held by the reporting persons represent beneficial ownership of 4.1% of the class of securities.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
     
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    -0-
    6
    SHARED VOTING POWER
     
    6,750,204 1
    7
    SOLE DISPOSITIVE POWER
     
    -0-
    8
    SHARED DISPOSITIVE POWER
     
    6,750,204 1
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    6,750,204 1
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (See Instructions)                         
                                                                                                                                                                [     ]
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.1% 1 2
    12
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    1 Includes 13,350 Shares for which Warrants are exercisable within the next 60 days.

    2 The percentages set forth herein are calculated based on 109,564,695 Shares outstanding as of November 2, 2023, as reported by the Company in its Form 10-Q filed with the SEC on November 6, 2023, as adjusted and approximated for the issuance of Shares in connection with the Company’s acquisition of EQRx, Inc., as described by the Company in its Form 8-K filed with the SEC on November 9, 2023.  The Reporting Persons calculate that there are 163,796,510 Shares outstanding as so adjusted and approximated.


    Page 30 of 34 Pages


    This Amendment No. 1 to Schedule 13G amends and restates in its entirety the Schedule 13G initially filed on November 9, 2023 (together with all prior and current amendments thereto, this “Schedule 13G”).

    Preliminary Note:

    As of the date of this report, the Farallon Funds hold an aggregate of: (i) 6,736,854 Shares; and (ii) 120,085 Common Stock Purchase Warrants (the “Warrants”), each of which currently is exercisable, pursuant to the terms thereof, to purchase 0.1112 Shares.

    Capitalized terms used in this Preliminary Note without definitions have the meanings ascribed to them below.

    Item 1.
    Issuer

    (a) Name of Issuer:

        Revolution Medicines, Inc. (the “Company”)

    (b) Address of Issuer’s Principal Executive Offices:

        700 Saginaw Drive, Redwood City, CA 94063

    Item 2.
    Identity and Background

    Title of Class of Securities and CUSIP Number (Items 2(d) and (e))

    This statement relates to shares of Common Stock, par value $0.0001 per share (the “Shares”) of the Company.  The CUSIP number of the Shares is 76155X100.

    Name of Persons Filing, Address of Principal Business Office and Citizenship (Items 2(a), (b) and (c))

    This statement is filed by the entities and persons listed below, all of whom together are referred to herein as the “Reporting Persons.”

    The Farallon Funds

    (i)
                Farallon Capital Partners, L.P., a California limited partnership (“FCP”), with respect to the Shares held by it and the Shares that it has the right to acquire upon the exercise of Warrants;

    (ii)
                Farallon Capital Institutional Partners, L.P., a California limited partnership (“FCIP”), with respect to the Shares held by it and the Shares that it has the right to acquire upon the exercise of Warrants;

    (iii)
     Farallon Capital Institutional Partners II, L.P., a California limited partnership (“FCIP II”), with respect to the Shares held by it and the Shares that it has the right to acquire upon the exercise of Warrants;

    (iv)
     Farallon Capital Institutional Partners III, L.P., a Delaware limited partnership (“FCIP III”), with respect to the Shares held by it and the Shares that it has the right to acquire upon the exercise of Warrants;

    (v)
                 Four Crossings Institutional Partners V, L.P., a Delaware limited partnership (“FCIP V”), with respect to the Shares held by it and the Shares that it has the right to acquire upon the exercise of Warrants;

    (vi)
     Farallon Capital Offshore Investors II, L.P., a Cayman Islands exempted limited partnership (“FCOI II”), with respect to the Shares held by it and the Shares that it has the right to acquire upon the exercise of Warrants;

    (vii)
     Farallon Capital (AM) Investors, L.P., a Delaware limited partnership (“FCAMI”), with respect to the Shares held by it and the Shares that it has the right to acquire upon the exercise of Warrants;

    (viii)
    Farallon Capital F5 Master I, L.P., a Cayman Islands exempted limited partnership (“F5MI”), with respect to the Shares held by it and the Shares that it has the right to acquire upon the exercise of Warrants; and

    (ix)
      Farallon Healthcare Partners Master, L.P., a Cayman Islands exempted limited partnership (“FHPM”), with respect to the Shares held by it.

    FCP, FCIP, FCIP II, FCIP III, FCIP V, FCOI II, FCAMI, F5MI and FHPM are together referred to herein as the “Farallon Funds.”

    The Farallon General Partner

    (x)
              Farallon Partners, L.L.C., a Delaware limited liability company (the “Farallon General Partner”), which is the general partner of each of FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI and the sole member of each of the FCIP V General Partner (as defined below) and the FHPM General Partner (as defined below), with respect to the Shares held by each of the Farallon Funds other than F5MI and the Shares that each of the Farallon Funds other than F5MI has the right to acquire upon the exercise of Warrants.

    The FCIP V General Partner

    (xi)
    Farallon Institutional (GP) V, L.L.C., a Delaware limited liability company (the “FCIP V General Partner”), which is the general partner of FCIP V, with respect to the Shares held by FCIP V and the Shares that FCIP V has the right to acquire upon the exercise of Warrants.

    The F5MI General Partner

    (xii)
    Farallon F5 (GP), L.L.C., a Delaware limited liability company (the “F5MI General Partner”), which is the general partner of F5MI, with respect to the Shares held by F5MI and the Shares that F5MI has the right to acquire upon the exercise of Warrants.

    The FHPM General Partner

    (xiii)
    Farallon Healthcare Partners (GP), L.L.C., a Delaware limited liability company (the “FHPM General Partner”), which is the general partner of FHPM, with respect to the Shares held by FHPM.

    The Farallon Individual Reporting Persons

    (xiv)
    The following persons, each of whom is a managing member or senior managing member, as the case may be, of the Farallon General Partner and a manager or senior manager, as the case may be, of the FCIP V General Partner, the F5MI General Partner and the FHPM General Partner, with respect to the Shares held by the Farallon Funds and the Shares that the Farallon Funds have the right to acquire upon the exercise of Warrants:  Joshua J. Dapice (“Dapice”); Philip D. Dreyfuss (“Dreyfuss”); Hannah E. Dunn (“Dunn”); Richard B. Fried (“Fried”); Varun N. Gehani (“Gehani”); Nicolas Giauque (“Giauque”); David T. Kim (“Kim”); Michael G. Linn (“Linn”); Rajiv A. Patel (“Patel”); Thomas G. Roberts, Jr. (“Roberts”); Edric C. Saito (“Saito”); William Seybold (“Seybold”); Daniel S. Short (“Short”); Andrew J. M. Spokes (“Spokes”); John R. Warren (“Warren”); and Mark C. Wehrly (“Wehrly”).

    Dapice, Dreyfuss, Dunn, Fried, Gehani, Giauque, Kim, Linn, Patel, Roberts, Saito, Seybold, Short, Spokes, Warren and Wehrly are together referred to herein as the “Farallon Individual Reporting Persons.”

    The citizenship of each of the Farallon Funds, the Farallon General Partner, the FCIP V General Partner, the F5MI General Partner and the FHPM General Partner is set forth above.  Each of the Farallon Individual Reporting Persons, other than Giauque and Spokes, is a citizen of the United States.  Giauque is a citizen of France. Spokes is a citizen of the United Kingdom.  The address of the principal business office of each of the Reporting Persons is c/o Farallon Capital Management, L.L.C., One Maritime Plaza, Suite 2100, San Francisco, California 94111.


    Page 31 of 34 Pages


    Item 3.
    If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c),         Check Whether the Person Filing Is an Entity Specified in (a) - (k):

    Not applicable.

    Item 4.
    Ownership

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.

    The Shares and Warrants reported hereby for the Farallon Funds are owned directly by the Farallon Funds. The Farallon General Partner, as general partner of FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI and the sole member of the FCIP V General Partner and the FHPM General Partner, may be deemed to be a beneficial owner of all such Shares and Warrants owned by the Farallon Funds other than F5MI.  The FCIP V General Partner, as general partner of FCIP V, may be deemed to be a beneficial owner of all such Shares and Warrants owned by FCIP V. The F5MI General Partner, as general partner of F5MI, may be deemed to be a beneficial owner of all such Shares and Warrants owned by F5MI.  The FHPM General Partner, as general partner of FHPM, may be deemed to be a beneficial owner of all such Shares owned by FHPM.  Each of the Farallon Individual Reporting Persons, as a managing member or senior managing member, as the case may be, of the Farallon General Partner and a manager or senior manager, as the case may be, of the FCIP V General Partner, the F5MI General Partner and the FHPM General Partner, in each case with the power to exercise investment discretion, may be deemed to be a beneficial owner of all such Shares and Warrants owned by the Farallon Funds.  Each of the Farallon General Partner, the FCIP V General Partner, the F5MI General Partner, the FHPM General Partner and the Farallon Individual Reporting Persons hereby disclaims any beneficial ownership of any such Shares and Warrants.

    Item 5.
    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be a beneficial owner of more than five percent of the class of securities, check the following: [X]

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     Not applicable.

    Item 8.
    Identification and Classification of Members of the Group

    The Reporting Persons are filing this Schedule 13G pursuant to Section 240.13d-1(c).  Consistent with Item 2 of the cover page for each Reporting Person above, the Reporting Persons neither disclaim nor affirm the existence of a group among them.

    Item 9.
    Notice of Dissolution of Group

    Not applicable.

    Item 10.
    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.


    Page 32 of 34 Pages


    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    Dated:  February 12, 2024

     
    /s/ Hannah E. Dunn
     
    FARALLON PARTNERS, L.L.C.,
     
    On its own behalf and
     
    As the General Partner of
     
    FARALLON CAPITAL PARTNERS, L.P.,
     
    FARALLON CAPITAL INSTITUTIONAL PARTNERS, L.P.,
     
    FARALLON CAPITAL INSTITUTIONAL PARTNERS II, L.P.,
     
    FARALLON CAPITAL INSTITUTIONAL PARTNERS III, L.P.,
     
    FARALLON CAPITAL OFFSHORE INVESTORS II, L.P. and
     
    FARALLON CAPITAL (AM) INVESTORS, L.P.
     
    By Hannah E. Dunn, Managing Member
       
     
    /s/ Hannah E. Dunn
     
    FARALLON INSTITUTIONAL (GP) V, L.L.C.
     
    On its own behalf and
     
    As the General Partner of
     
    FOUR CROSSINGS INSTITUTIONAL PARTNERS V, L.P.
     
    By Hannah E. Dunn, Manager
       
     
    /s/ Hannah E. Dunn
     
    FARALLON F5 (GP), L.L.C.
     
    On its own behalf and
     
    As the General Partner of
     
    FARALLON CAPITAL F5 MASTER I, L.P.
     
    By Hannah E. Dunn, Manager
       
     
    /s/ Hannah E. Dunn
     
    FARALLON HEALTHCARE PARTNERS (GP), L.L.C.
     
    On its own behalf and
     
    As the General Partner of
     
    FARALLON HEALTHCARE PARTNERS MASTER, L.P.
     
    By Hannah E. Dunn, Manager
       
     
    /s/ Hannah E. Dunn
     
    Hannah E. Dunn, individually and as attorney-in-fact for each of Joshua J. Dapice, Philip D. Dreyfuss, Richard B. Fried, Varun N. Gehani, Nicolas Giauque, David T. Kim, Michael G. Linn, Rajiv A. Patel, Thomas G. Roberts, Jr., Edric C. Saito, William Seybold, Daniel S. Short, Andrew J. M. Spokes, John R. Warren and Mark C. Wehrly

    The Powers of Attorney executed by each of Dapice, Dreyfuss, Fried, Gehani, Giauque, Kim, Linn, Patel, Roberts, Saito, Seybold, Short, Spokes, Warren and Wehrly authorizing Dunn to sign and file this Schedule 13G on his behalf, which were filed as exhibits to the Schedule 13G filed with the Securities and Exchange Commission on January 31, 2023 by such Reporting Persons with respect to the Class A Ordinary Shares of ARYA Sciences Acquisition Corp IV, are hereby incorporated by reference.


    Page 33 of 34 Pages


    EXHIBIT INDEX


    EXHIBIT 1
    Joint Acquisition Statement Pursuant to Section 240.13d-1(k) (previously filed)
     


    Page 34 of 34 Pages
    Get the next $RVMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RVMD

    DatePrice TargetRatingAnalyst
    7/16/2024$46.00 → $62.00Buy
    Needham
    7/12/2024$52.00Overweight
    Barclays
    7/8/2024$63.00Buy
    Jefferies
    4/12/2024$36.00 → $46.00Buy
    Needham
    4/10/2024$36.00 → $48.00Outperform → Strong Buy
    Raymond James
    3/11/2024$43.00Overweight
    Piper Sandler
    1/5/2024$31.00 → $34.00Neutral → Buy
    BofA Securities
    1/4/2024$41.00Outperform
    Wedbush
    More analyst ratings

    $RVMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

      Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this yearNew non-small cell lung cancer clinical data from RAS(ON) inhibitor portfolio support strategies for first-line metastatic and earlier lines of treatmentAnthony Mancini joins as chief global commercialization officerRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial

      5/7/25 4:02:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025

      REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2025 on Wednesday, May 7, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live web

      4/30/25 4:05:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Barbara Weber, M.D., Elected to ITM Supervisory Board

      Garching / Munich, Germany, April 09, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the election of Barbara Weber, M.D., to its Supervisory Board, effective May 01, 2025. The election occurred at ITM's Extraordinary General Meeting. Dr. Weber is the President, Chief Executive Officer and Founder of Tango Therapeutics (NASDAQ:TNGX). She has over 25 years of executive and research and development leadership experience in biotech, venture capital and at major pharmaceutical companies, including Novartis (NYSE:NVS) and GlaxoSmithKline (NYSE:GSK). ITM's Supervisory Board and the company overall will benefit from Dr. Weber's deep ex

      4/9/25 5:00:00 AM ET
      $BNTX
      $GSK
      $NVS
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $RVMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham reiterated coverage on Revolution Medicines with a new price target

      Needham reiterated coverage of Revolution Medicines with a rating of Buy and set a new price target of $62.00 from $46.00 previously

      7/16/24 8:15:42 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Barclays initiated coverage on Revolution Medicines with a new price target

      Barclays initiated coverage of Revolution Medicines with a rating of Overweight and set a new price target of $52.00

      7/12/24 7:33:26 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies initiated coverage on Revolution Medicines with a new price target

      Jefferies initiated coverage of Revolution Medicines with a rating of Buy and set a new price target of $63.00

      7/8/24 8:13:53 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RVMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Schroeder Thilo bought $59,999,962 worth of shares (1,304,347 units at $46.00) (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      12/9/24 4:15:16 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RVMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Revolution Medicines Inc.

      SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

      11/8/24 10:52:39 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

      SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

      2/14/24 6:30:27 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

      SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

      2/14/24 9:26:21 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RVMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Director Clyburn Frank

      4/A - Revolution Medicines, Inc. (0001628171) (Issuer)

      4/28/25 6:27:35 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • General Counsel Cislini Jeff sold $79,008 worth of shares (2,041 units at $38.71), decreasing direct ownership by 3% to 57,723 units (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      3/24/25 4:55:57 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • General Counsel Cislini Jeff sold $56,921 worth of shares (1,458 units at $39.04), decreasing direct ownership by 2% to 59,764 units (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      3/19/25 5:43:42 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RVMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Circle Pharma Appoints Stephen Kelsey, MB ChB, MD, to its Board of Directors

      Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Stephen Kelsey as an independent member of its Board of Directors. Dr. Kelsey has extensive experience in oncology clinical development. He currently serves as president, head of research and development and chief medical officer at Revolution Medicines (NASDAQ:RVMD), and previously held roles including president of Onkaido Therapeutics, the oncology-focused unit of Moderna (NASDAQ:MRNA), senior vice president of new products at Medivation (acquired by Pfizer (NYSE: PFE)), executive vice president and chief medical officer at Geron Corporation (NASDAQ

      12/15/22 7:00:00 AM ET
      $GERN
      $MRNA
      $PFE
      $RVMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors

      REDWOOD CITY, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the appointment of Lorence Kim, M.D., to its board of directors. Dr. Kim has made significant contributions across the biotechnology and financial industries during his career at Moderna and Goldman Sachs. He has extensive operational expertise and an extraordinary track record in raising capital for high-growth health care companies. Dr. Kim will serve as an independent director for the remaining term of Neil Exter, who is stepping down after serving as a director most recently since 2019

      7/13/22 7:00:00 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RVMD
    SEC Filings

    See more
    • SEC Form 10-Q filed by Revolution Medicines Inc.

      10-Q - Revolution Medicines, Inc. (0001628171) (Filer)

      5/7/25 4:10:24 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Revolution Medicines, Inc. (0001628171) (Filer)

      5/7/25 4:05:10 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Revolution Medicines Inc.

      DEFA14A - Revolution Medicines, Inc. (0001628171) (Filer)

      4/29/25 4:39:20 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RVMD
    Financials

    Live finance-specific insights

    See more
    • Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

      Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this yearNew non-small cell lung cancer clinical data from RAS(ON) inhibitor portfolio support strategies for first-line metastatic and earlier lines of treatmentAnthony Mancini joins as chief global commercialization officerRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial

      5/7/25 4:02:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025

      REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2025 on Wednesday, May 7, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live web

      4/30/25 4:05:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

      Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data readout in 2026Company is activating study sites for Phase 3 RASolve 301 trial of daraxonrasib in previously treated locally advanced or metastatic RAS mutant non-small cell lung cancerCompany anticipates initiating two additional registrational trials of daraxonrasib in earlier lines of treatment for pancreatic cancer in the second half of 2025Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NA

      2/26/25 4:02:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care